Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 30, 2020

View Archived Issues

Enrollment ongoing in phase I/II study of HPN-328 in advanced cancer

Initiation of phase I/II study of NGM-621 as therapy in patients with SARS-CoV-2 infection

First-in-human data for the personalized multitarget adoptive cell therapy ACTolog

Researchers develop a novel murine model of deer tick virus infection

FDA approves Imcivree as first-ever therapy for POMC, PCSK1 or LEPR deficiency obesities

Cabometyx approved in Japan for unresectable previously treated HCC

SmartPharm awarded contract for development of gene-encoded antibody against COVID-19

Results of a phase Ib trial evaluating the microR-132 inhibitor CDR-132L in heart failure

VBI Vaccines presents data from part B of ongoing phase I/IIa study of VBI-1901

CVI Pharmaceuticals details preclinical and first-in-human data for CVI-LM001

Pelareorep plus GM-CSF shows efficacy, safety and tolerability in ReoGlio study

ST6GAL1 as serum marker to identify HCC patients who may benefit from lenvatinib therapy

University of Bern, Silence Therapeutics describe nucleic acids inhibiting PROS1

COLCORONA trial of colchicine in COVID-19 recommended to continue enrollment

Janssen discovers anti-HBV compounds

New CD134 agonists identified at Bicycle Therapeutics

Eisai and Wren Therapeutics collaborate to target alpha-synuclein to treat synucleinopathies

Qilu Regor Therapeutics presents new CDK inhibitors

New EZH2 inhibitors synthesized at PharmaBlock Sciences

DAY-101 well tolerated, shows antitumor activity in patients with recurrent low-grade glioma

Phase III study of NC-6004 in pancreatic cancer concludes

European Commission approves Dupixent for severe atopic dermatitis in children aged 6-11 years

Novel potent and selective thyroid hormone receptor beta agonists as therapeutic agents in NASH

New PDE4 inhibitor shows preclinical antifibrotic effect by inhibiting lung macrophage activity

Hookipa reports interim phase II data on prophylactic CMV vaccine candidate HB-101

Japan first to approve Humira for pyoderma gangrenosum

Moderna to file for EUA of mRNA-1273 for COVID-19 following primary efficacy analysis